Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.67 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30270561 | 1.00 | CYP3A4 (0.67) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL12343824 | 0.89 | CYP3A4 (0.58) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL15259275 | 0.89 | CYP3A4 (0.58) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL8234259 | 0.88 | CYP3A4 (0.57) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL31066572 | 0.87 | CYP3A4 (0.63) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL18697423 | 0.87 | CYP3A4 (0.56) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL17189358 | 0.87 | CYP3A4 (0.56) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL12982022 | 0.87 | CYP3A4 (0.56) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL21828671 | 0.85 | CYP3A4 (0.68) | CYP3A4SLC7A5NLN | |
| SCHEMBL29728766 | 0.85 | CYP3A4 (0.60) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111819191-B | Chemoenzymatic synthesis of liraglutide, soxhlet Ma Lutai and GLP-1 | 费森尤斯卡比有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | claimed |
| CN-117202936-A | Glucagon-like peptide compounds | 诺华股份有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-116519811-A | System for predicting blood glucose level of pregnant individual | 杭州凯莱谱精准医疗检测技术有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-116519812-A | Application of biomarker in preparation of gestational diabetes diagnostic reagent | 杭州凯莱谱精准医疗检测技术有限公司 | 2023-08-01 | — | — | CN | claimed |
| EP-3758730-B1 | PEPTIDES AND COMPOSITIONS FOR USE IN COSMETICS AND MEDICINE | LIPOTRUE S L (ES) | 2022-11-02 | — | — | EP | claimed |
| US-20260036547-A1 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | ASTRAZENECA AB (SE) | 2026-02-05 | — | — | US | disclosed |
| WO-2025259130-A1 | USE OF AC-HIS-ALA-GLU-GLU-NH2 PEPTIDE TO REMEDY DEFICIT OF AN ENDOGENOUS COMPONENT OF ANIMAL BLOOD | CONSUMER COOPERATIVE "VSE" | 2025-12-18 | — | — | WO | disclosed |
| WO-2025259133-A1 | AC-HIS-ALA-GLU-GLU-NH2 PEPTIDE AND DERIVATIVES THEREOF FOR REMEDYING DEFICIT OF AN ENDOGENOUS COMPONENT OF HUMAN BLOOD | Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации | 2025-12-18 | — | — | WO | disclosed |
| US-20250368605-A1 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2025-12-04 | — | — | US | disclosed |
| US-20250277001-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2025-09-04 | — | — | US | disclosed |
| EP-4554968-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | Centessa Pharmaceuticals (UK) Limited (GB) | 2025-05-21 | — | — | EP | disclosed |
| US-12297260-B2 | DKK1 antibodies and methods of use | AMGEN INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-109963848-B | Substituted N- (3-fluoropropyl) -pyrrolidine compounds, preparation thereof and therapeutic use thereof | 赛诺菲 | 2022-07-05 | — | — | CN | disclosed |
| CN-103477224-B | Blood collection device containing lysophospholipase inhibitor | BECTON, DICKINSON AND CO. (US) | 2015-12-23 | — | — | CN | disclosed |
| CN-103477224-A | Blood collection device containing lysophospholipase inhibitor | BECTON DICKINSON CO | 2013-12-25 | — | — | CN | disclosed |
| CN-1269528-C | Application of dipeptide base peptidase IV effector for reducing blood sugar level of mammal | BIOLOG MEDICINE AG (GB) | 2006-08-16 | — | — | CN | disclosed |
| CN-1535681-A | Application of dipeptide base peptidase IV effector for reducing blood sugar level of mammal | ӡ��ҩƷ�ɷ�����˾ | 2004-10-13 | — | — | CN | disclosed |
| CN-1132578-C | Use of dipeptidyl peptidase IV effectors to lower blood glucose levels in mammals | BIOLOG DRUG REAGENTS FOR PHARM (DE) | 2003-12-31 | — | — | CN | disclosed |
| CN-1216468-A | Use of dipeptidyl peptidase IV effectors to lower blood glucose levels in mammals | BIOLOG DRUG REAGENTS FOR PHARM (DE) | 1999-05-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368605-A1 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof | CYP19A1, ESR1, ESR2 | CYP3A4 168/4885SLC7A5 2562/4885HRH4 217/4885 |
| US-20250277001-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | HCRTR2, HCRTR1, CRH | CYP3A4 907/4885SLC7A5 1787/4885HRH4 218/4885 |
| US-20260036547-A1 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | ATP5ME, ATP5MF, ATP5MK | CYP3A4 1949/4885SLC7A5 1133/4885HRH4 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.